Serotonin Type 3 Receptor Genes:
            <i>HTR3A, B, C, D, E</i>

Niesler, Beate; Kapeller, Johannes; Hammer, Christian; Rappold, Gudrun

doi:10.2217/14622416.9.5.501

Cited by 79 publications

(69 citation statements)

References 31 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5-HTR3A and HTR3B polymorphisms may also contribute to the etiology of psychiatric disorders and serve as predictors in CINV and in the medical treatment of psychiatric patients. (Niesler et al 2008). iii.…”

Section: Insulin Receptor(insr)mentioning

confidence: 98%

Pharmacogenetics: The Scientific Basis

Banjoko¹

2012

Pharmacology

View full text Add to dashboard Cite

Section: Insulin Receptor(insr)mentioning

confidence: 98%

Pharmacogenetics: The Scientific Basis

Banjoko¹

2012

Pharmacology

View full text Add to dashboard Cite

“…However, 5-HT 3 A and 5-HT 3 AB receptors differ in their allosteric regulation by some general anaesthetic agents, small alcohols and indoles [158,317,341]. The potential diversity of 5-HT 3 receptors is increased by alternative splicing of the genes HTR 3 A and E [44,151,276,278,279]. In addition, the use of tissue-specific promoters driving expression from different transcriptional start sites has been reported for the HTR3A, HTR3B, HTR3D and HTR3E genes, which could result in 5-HT 3 subunits harbouring different N-termini [176,276,366].…”

Section: Receptorsmentioning

confidence: 99%

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Ligand‐gated ion channels

Alexander

Peters

Kelly

et al. 2017

British J Pharmacology

143

129

View full text Add to dashboard Cite

The Concise Guide to PHARMACOLOGY 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13879/full. Ligand-gated ion channels are one of the eight major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2017, and supersedes data presented in the 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature Committee of the Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate. Conflict of interestThe authors state that there are no conflicts of interest to declare. Overview: Ligand-gated ion channels (LGICs) are integral membrane proteins that contain a pore which allows the regulated flow of selected ions across the plasma membrane. Ion flux is passive and driven by the electrochemical gradient for the permeant ions. These channels are open, or gated, by the binding of a neurotransmitter to an orthosteric site(s) that triggers a conformational change that results in the conducting state. Modulation of gating can occur by the binding of endogenous, or exogenous, modulators to allosteric sites.LGICs mediate fast synaptic transmission, on a millisecond time scale, in the nervous system and at the somatic neuromuscular junction. Such transmission involves the release of a neurotransmitter from a pre-synaptic neurone and the subsequent activation of post-synaptically located receptors that mediate a rapid, phasic, electrical signal (the excitatory, or inhibitory, post-synaptic potential). However, in addition to their traditional role in phasic neurotransmission, it is now established that some LGICs mediate a tonic form of neuronal regulation that results from the activation of extra-synaptic receptors by ambient levels of neurotransmitter. The expression of some LGICs by nonexcitable cells is suggestive of additional ...

show abstract

“…However, 5-HT 3 A and 5-HT 3 AB receptors differ in their allosteric regulation by some general anaesthetic agents, small alcohols and indoles [146,293,314]. The potential diversity of 5-HT 3 receptors is increased by alternative splicing of the genes HTR3A and E [39,139,255,257,258]. In addition, the use of tissue-specific promoters driving expression from different transcriptional start sites has been reported for theHTR3A, HTR3B,HTR3D and HTR3E genes, which could result in 5-HT3 subunits harbouring different N-termini [160,255,339].…”

Section: Overviewmentioning

confidence: 99%

The Concise Guide to PHARMACOLOGY 2015/16: Ligand‐gated ion channels

Alexander

Peters

Kelly

et al. 2015

British J Pharmacology

128

View full text Add to dashboard Cite

The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/ doi/10.1111/bph.13350/full. Ligand-gated ion channels are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltagegated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The Concise Guide is published in landscape format in order to facilitate comparison of related targets. It is a condensed version of material contemporary to late 2015, which is presented in greater detail and constantly updated on the website www.guidetopharmacology.org, superseding data presented in the previous Guides to Receptors & Channels and the Concise Guide to PHARMACOLOGY 2013/14. It is produced in conjunction with NC-IUPHAR and provides the official IUPHAR classification and nomenclature for human drug targets, where appropriate. It consolidates information previously curated and displayed separately in IUPHAR-DB and GRAC and provides a permanent, citable, point-in-time record that will survive database updates. Conflict of InterestThe authors state that there are no conflicts of interest to declare. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.Overview: Ligand-gated ion channels (LGICs) are integral membrane proteins that contain a pore which allows the regulated flow of selected ions across the plasma membrane. Ion flux is passive and driven by the electrochemical gradient for the permeant ions. These channels are open, or gated, by the binding of a neurotransmitter to an orthosteric site(s) that triggers a conformational change that results in the conducting state. Modulation of gating can occur by the binding of endogenous, or exogenous, modulators to allosteric sites.LGICs mediate fast synaptic transmission, on a millisecond time scale, in the nervous system and at the somatic neuromuscular junction. Such transmission involves the release of a neurotransmitter from a pre-synaptic neurone and the subsequent activation of post-synaptically located receptors that mediate a rapid, phasic, electrical signal (the excitatory, or inhibitory, post-synaptic potential). However, in addition to their traditional role in phasic neurotransmission, it is now established that some LGICs mediate a tonic form of neuronal regulation that results from the activation of extra-synaptic receptors ...

show abstract

Serotonin Type 3 Receptor Genes: HTR3A, B, C, D, E

Cited by 79 publications

References 31 publications

Pharmacogenetics: The Scientific Basis

Pharmacogenetics: The Scientific Basis

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Ligand‐gated ion channels

The Concise Guide to PHARMACOLOGY 2015/16: Ligand‐gated ion channels

Contact Info

Product

Resources

About